Beyond specialisation: why integrated CDMO capabilities matter for next-gen therapies
Integrated CDMO capability connects discovery through clinical and commercial manufacturing, providing a single accountable partner across the full next-gen therapy lifecycle.
In this article, Sangkyu Hwang, Senior Director & Head of MSAT Technical Excellence at Samsung Biologics, shares why specialized expertise remains critical, but when capabilities are comparable, an integrated partner can offer a distinct advantage by reducing risks across development and manufacturing. He also explains how Samsung Biologics pairs 845,000L of world-class capacity with dedicated bioconjugation services for true end-to-end delivery— from ADCs to next-gen modalities.
Discover what sets an integrated CDMO partner apart in advancing the therapies of tomorrow.
Integrated CDMO capability connects discovery through clinical and commercial manufacturing, providing a single accountable partner across the full next-gen therapy lifecycle.
In this article, Sangkyu Hwang, Senior Director & Head of MSAT Technical Excellence at Samsung Biologics, shares why specialized expertise remains critical, but when capabilities are comparable, an integrated partner can offer a distinct advantage by reducing risks across development and manufacturing. He also explains how Samsung Biologics pairs 845,000L of world-class capacity with dedicated bioconjugation services for true end-to-end delivery— from ADCs to next-gen modalities.
Discover what sets an integrated CDMO partner apart in advancing the therapies of tomorrow.
Share article
Related Content